CUE vs AGIO vs IMVT vs BMY

For growth investors, Cue Biopharma, Inc.

(CUE) is the stronger pick with 195. 7% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Agios Pharmaceuticals, Inc. (AGIO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -89. 4% for Cue Biopharma, Inc. (CUE). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus CUE's -89. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bristol-Myers Squibb Company (BMY) is the lower-risk stock at 0.

50β versus Cue Biopharma, Inc. 's 2. 34β — meaning CUE is approximately 364% more volatile than BMY relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cue Biopharma, Inc.

(CUE) is pulling ahead at 195. 7% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, CUE leads at 180. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bristol-Myers Squibb Company (BMY) is the more profitable company, earning 14.

6% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMY leads at 26. 3% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — CUE leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMVT: 67.

2% to $45. 50.

In this comparison, BMY (4.

4% yield) pays a dividend. CUE, AGIO, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bristol-Myers Squibb Company (BMY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

50), 4. 4% yield). Cue Biopharma, Inc. (CUE) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BMY: +6. 7%, CUE: -89. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CUE is a small-cap high-growth stock; AGIO is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; BMY is a mid-cap deep-value stock. BMY pays a dividend while CUE, AGIO, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.